#LDL_C - Twitter Hashtag

9 days ago

The LDL-C–MH-MARS machine learning equation matched the Martin-Hopkins equation for #LDL_C accuracy and outperformed Friedewald, Sampson-NIH, and Modified Sampson equations in nearly 5 million US patients. https://t.co/LUfu9qLjlO

1

9

3

6

4K

JAMA Cardiology @JAMACardio

17 days ago

A digitally enabled quality improvement strategy modestly improved #LDL_C control and increased prescription of combination lipid-lowering therapy for patients with #ASCVD, but many remained above guideline targets. https://t.co/65jx66bpR6

0

6

0

5

2K

JAMA Cardiology @JAMACardio

2 months ago

A digitally enabled quality improvement strategy modestly improved #LDL_C control and increased prescription of combination lipid-lowering therapy for patients with #ASCVD, but many remained above guideline targets. https://t.co/bZ1uyAndB6

JAMACardio's tweet photo. A digitally enabled quality improvement strategy modestly improved #LDL_C control and increased prescription of combination lipid-lowering therapy for patients with #ASCVD, but many remained above guideline targets.

https://t.co/bZ1uyAndB6 https://t.co/iOCVEuRoGP

0

22

7

1

2K

JAMA Cardiology @JAMACardio

2 months ago

The LDL-C–MH-MARS machine learning equation matched the Martin-Hopkins equation for #LDL_C accuracy and outperformed Friedewald, Sampson-NIH, and Modified Sampson equations in nearly 5 million US patients. https://t.co/gh9g5CYpsa

JAMACardio's tweet photo. The LDL-C–MH-MARS machine learning equation matched the Martin-Hopkins equation for #LDL_C accuracy and outperformed Friedewald, Sampson-NIH, and Modified Sampson equations in nearly 5 million US patients.

https://t.co/gh9g5CYpsa https://t.co/omLAHWMj3P

0

9

4

2

2K

Tariq Mir 🇵🇰 @TSM_Humanist

8 months ago

Lepodisiran is a game changer. #LDL_C

0

2

1

263

cardio-met

@cardiomet_CE

10 months ago

4c) Which describes a main result from the Ph 3 #enlicitide oral #PCSK9i data vs placebo? a. ⬆️ serious adverse event rates b. ⬇️ LDL-C by nearly 60% versus placebo c. No effect on apolipoprotein B #apoB levels d. #LDL_C reduction inferior to that expected with inclisiran

1

0

1K

cardio-met

@cardiomet_CE

11 months ago

15b) Previously #CETPi was shown to yield quite impressive #LDL_C and #Lp(a)⬇️. At #ESC25 we saw very preliminary data on the CETPi #obicetrapib, in which data from 2 prior studies vs placebo were combined. Pts who received obicetrapib appear to have ⬇️#MACE.

1

2

0

1K

cardio-met

@cardiomet_CE

11 months ago

11a) Very exciting to see so much new data between #ESC25 and #AHA25 on advances in #LDL_C lowering! In addition to VESALIUS-CV, with CV outcomes and not just lipid-lowering results from an injectable #PCSK9i, we also expect at #AHA25 . . .

1

2

0

1K

cardio-met

@cardiomet_CE

11 months ago

7b) An important update in these guidelines is this important chart showing levels of risk and the target #LDL_C for each. They have added the category "extreme risk" (e.g., #polyvascular disease & pts with #ASCVD who have had recurrent events despite max tolerated #statins.

cardiomet_CE's tweet photo. 7b) An important update in these guidelines is this important chart showing levels of risk and the target #LDL_C for each. They have added the category "extreme risk" (e.g., #polyvascular disease & pts with #ASCVD who have had recurrent events despite max tolerated #statins. https://t.co/jH4FXgNbUt

1

3

0

833

د.صالح الغفيلي

@dralghofaili

about 1 year ago

أن #LDL_C (الكوليسترول الضار) هو أحد أكثر عوامل الخطر القابلة للتحكم؟ دراسة شاملة أثبتت: كل انخفاض 1 ملي مول/لتر (39 ملجم/ديسيلتر) في LDL-C يقلل بشكل كبير من خطر الإصابة بأمراض القلب والأوعية الدموية. #استشارى_قلب #استشارى_قسطرة #صحة_قلبك

1

4

0

603

cardio-met

@cardiomet_CE

over 2 years ago

8a) As we have seen, in #CLEAR_Outcomes #bempedoic acid ➡️significant ⬇️#LDL_C & ⬇️ #CV risk in statin-intolerant ppl with, or at high risk for, #CVD by 13%. #Hispanic/#Latinx ppl have been underrepresented in clinical trials investigating lipid & #ASCVD management.

1

2

1

0

3K

cardio-met

@cardiomet_CE

over 2 years ago

6c) In #CLEAR_Outcomes, #bempedoic_acid #BA⬇️#LDL_C & significantly ⬇️ #CV risk in statin-intolerant ppl with, or at high risk for, #CVD vs placebo. 🆕This pre-specified secondary analysis compared outcomes by pt-reported sex.

1

2

0

3K

cardio-met

@cardiomet_CE

almost 3 years ago

10a) More from #AHA23! So, #hsCRP as a marker for #ASCVD risk. On 13NOV the esteemed #lipidologist #PaulRidkerMD presented 🆕 data from #CLEAR_OUTCOMES: #bempedoic_acid v placebo in 13,970 pts with #ASCVD or high #CV risk, #LDL_C 100+, & documented #statin intolerance.

cardiomet_CE's tweet photo. 10a) More from #AHA23! So, #hsCRP as a marker for #ASCVD risk.
On 13NOV the esteemed #lipidologist #PaulRidkerMD presented 🆕 data from #CLEAR_OUTCOMES: #bempedoic_acid v placebo in 13,970 pts with #ASCVD or high #CV risk, #LDL_C 100+, & documented #statin intolerance. https://t.co/jmXk7uh3DU

1

2

1

0

2K

cardio-met

@cardiomet_CE

about 3 years ago

7a) The #statins, the predominant approach to #LDL_C lowering, has a sustained safety record. For example, see 🔓https://t.co/CnBAv3jCBZ and this:

cardiomet_CE's tweet photo. 7a) The #statins, the predominant approach to #LDL_C lowering, has a sustained safety record. For example, see 🔓https://t.co/CnBAv3jCBZ and this: https://t.co/DVGHVfu25E

1

5

1

0

2K

cardio-met

@cardiomet_CE

about 3 years ago

6c) If a patient has elevated #LDL_C levels but indicators of #ASCVD risk are persistent despite effective #LLT such as #statins, one must consider the possibility of additional risk from elevated Lp(a), which is not ⬇️ by statins.

1

5

1

0

1K

cardio-met

@cardiomet_CE

about 3 years ago

26d) It's a. Lp(a) makes only a small contribution to measured #LDL_C levels but can be very important for risk prediction. Unfortunately, it must be measured separately using lectin-based, ultracentrifugation, or immunofixation electrophoresis methods not available everywhere.

1

4

1

1K

cardio-met

@cardiomet_CE

about 3 years ago

23) Lp(a) levels are genetically predetermined; we need ✔️only once. Lp(a) contributes a small portion of measured #LDL_C, but it cannot be estimated from traditional lipid panel. It must be measured directly! This is 🔑because as much as 20% of the population has ⬆️Lp(a)!

cardiomet_CE's tweet photo. 23) Lp(a) levels are genetically predetermined; we need ✔️only once. Lp(a) contributes a small portion of measured #LDL_C, but it cannot be estimated from traditional lipid panel. It must be measured directly!
This is 🔑because as much as 20% of the population has ⬆️Lp(a)! https://t.co/MfeqHiMOCd

1

4

1

0

1K

cardio-met

@cardiomet_CE

about 3 years ago

18) Indeed, the 2019 ESC Guidelines recommend targeting even lower #LDL_C levels in very high-risk patients, and use parameters from #IMPROVE_IT, #ODYSSEY_OUTCOMES, & #FOURIER to guide LDL-C goals. 🔓 https://t.co/3GCiFUI0bO

cardiomet_CE's tweet photo. 18) Indeed, the 2019 ESC Guidelines recommend targeting even lower #LDL_C levels in very high-risk patients, and use parameters from #IMPROVE_IT, #ODYSSEY_OUTCOMES, & #FOURIER to guide LDL-C goals.
🔓 https://t.co/3GCiFUI0bO https://t.co/d0ICoszMPn

1

4

1

1K

cardio-met

@cardiomet_CE

about 3 years ago

17) So how does #riskstratification guide primary prevention? Well, we know that ⬆️ #LDL_C is causal for #atherosclerosis and that the benefit of #statins in ⬇️LDL is unquestioned. 🔓 https://t.co/hdc7jzhJem 🔓 https://t.co/F1BwfgV2yZ 🔓 https://t.co/gImMKV57RU